A new study published in Diabetes Research and Clinical Practice explored trends and disparities in statin utilization and low-density lipoprotein cholesterol (LDL-C) levels among patients with diabetes aged 40-75 years. This study enrolled 4,860 patients from the National Health and Nutrition Examination Survey, 1999 to 2014. The findings revealed that during the study period the prevalence of statin use increased from 26.2-49.5%. Meanwhile, a continuous decrease in the mean LDL-C level, from 115.8-103.3 mg/dL was noted. Yet, the use of the 2013 American College of Cardiology/American Heart Association Guideline-defined high-potency statin medications, such as rosuvastatin, remained largely unchanged (from 14.0-17.9%). On the other hand, it was observed that statin utilization increased with age. However, women and African-Americans were 10% and 16% less likely to receive statin treatment, respectively. On the other hand, the use of rosuvastatin was associated with an average LDL-C reduction of 8.0 mg/dL. From the results, it was acknowledged that statin therapy remains underutilized in certain subgroups of patients.